奥沙利铂联合卡培他滨对结肠癌术后辅助化疗患者T淋巴细胞亚群及肿瘤标志物的影响

Impact of oxaliplatin combined with capecitabine on T lymphocyte subsets and tumor markers in postoperative adjuvant chemotherapy patients with colon cancer

摘要:

目的 探究奥沙利铂联合卡培他滨对结肠癌术后辅助化疗患者淋巴细胞亚群及肿瘤标志物的影响。方法 选择2021年7月至2024年7月九江市第一人民医院收治的70例结肠癌术后患者，按随机数字表法分为对照组和观察组，各35例。对照组予以卡培他滨辅助化疗，观察组联合奥沙利铂辅助化疗，两组均以21 d为1个疗程，持续治疗3个疗程。对比两组临床疗效、T淋巴细胞亚群、肿瘤标志物、不良反应。结果 观察组总缓解率（ORR）（74.29%）、疾病控制率（DCR）（94.29%）均较对照组（51.43%、77.14%）高，有统计学差异（P＜0.05）；观察组治疗后CD3⁺（59.62±4.27）%、CD4⁺（41.39±5.76）%均较对照组高，CD8⁺（21.05±1.79）%较对照组低，癌胚抗原（CEA）（12.33±1.16）μg/L、碱性成纤维细胞生长因子（bFGF）（41.05±3.17）pg/L、恶性肿瘤相关物质群（TSGF）（51.25±3.22）U/mL、糖类抗原（CA）125（28.14±1.77）kU/L、CA199（24.22±2.16）kU/L均较对照组低，有统计学差异（P＜0.05）；对比两组不良反应发生率，无统计学差异（P＞0.05）。结论 结肠癌术后患者予以奥沙利铂联合卡培他滨辅助化疗可有效调节肿瘤标志物水平，改善免疫功能，且安全性高。

Abstract:

Objective To explore the impact of adjuvant chemotherapy with oxaliplatin combined with capecitabine on T lymphocyte subsets and tumor markers in patients with colon cancer after surgery.Methods From July 2021 to July 2024, 70 patients with colon cancer after surgery admitted to First People's Hospital of Jiujiang City were selected and divided into control group and observation group by random number table method, with 35 patients in each group. The patients in control group received adjuvant chemotherapy with capecitabine, while the patients in observation group received adjuvant chemotherapy capecitabine and oxaliplatin. Both groups received treatment for three courses, with each course lasting 21 days. The clinical efficacy, T lymphocyte subsets, tumor markers, and adverse reactions were compared between the two groups.Results The overall remission rate (ORR) and disease control rate (DCR) of observation group (74.29%, 94.29%) were higher than those of control group (51.43%, 77.14%), with statistical difference (P＜0.05). After treatment, CD3⁺ (59.62±4.27) % and CD4⁺ (41.39±5.76) % of observation group were higher those of control group, and CD8⁺ (21.05±1.79)% was lower that of control group. Carcinoembryonic antigen (CEA) (12.33±1.16) μg/L, basic fibroblast growth factor (bFGF) (41.05±3.17) pg/L, malignancy related substance group (TSGF) (51.25±3.22) U/mL, carbohydrate antigen (CA) 125 (28.14±1.77) kU/L, CA199 (24.22±2.16) kU/L were lower than those of control group, with statistical difference (P＜0.05). There was no significant difference in adverse reactions between the two groups (P＞0.05).Conclusion Adjuvant chemotherapy with oxaliplatin combined with capecitabine in patients with colon cancer after surgery can effectively regulate tumor marker levels, improve immune function, and is safe.